L-Carnitine research

The L-Carnitine evidence base cited here is 4 sources — 3 clinical, 1 regulatory. Its strongest evidence is human — 3 clinical studies, most recently 2021 ("L-Carnitine L-Tartrate and Exercise Recovery — Randomized Controlled Tri…"). Regulatory status: FDA-approved (Carnitor).

• L-Carnitine is NOT a peptide — it's a small amino-acid derivative (~161 Da), synthesized in the body from lysine and methionine, essential for transporting long-chain fatty acids into mitochondria for energy production.
• It is genuinely FDA-approved (as Carnitor) for primary and secondary carnitine deficiency and for dialysis patients — one of the few approved items in this library — and has the strongest peer-reviewed evidence base here.
• Two clinically meaningful interactions to flag: it may enhance anticoagulants (warfarin/acenocoumarol) and may inhibit thyroid hormone action — worth real attention, unlike most 'interactions' in this space.

L-Carnitine (levocarnitine) is a naturally occurring compound central to fat metabolism: it carries long-chain fatty acids into the mitochondria where they're burned for energy. It's concentrated in high-energy tissues — heart, brain, skeletal muscle — and the body makes its own, so true deficiency is uncommon outside specific medical conditions.

L-Carnitine is a small molecule (~161 Da), not a peptide — it's a quaternary ammonium compound derived from the amino acids lysine and methionine. Several forms exist for different uses: acetyl-L-carnitine (ALCAR) is favored for cognitive research, L-carnitine L-tartrate (LCLT) for exercise recovery, and propionyl-L-carnitine (PLC) for cardiovascular applications.

L-Carnitine is the obligatory shuttle for the 'carnitine shuttle': it binds long-chain fatty acids and ferries them across the inner mitochondrial membrane so they can undergo beta-oxidation (fat burning). Without adequate carnitine, fat can't be efficiently used for energy. It also helps buffer the mitochondrial acyl-CoA pool, supports energy production in the heart and muscle, and has antioxidant and ammonia-lowering effects.

• Cardiovascular secondary prevention (2013, Mayo Clinic meta-analysis, 13 trials, 3,629 patients): associated with ~27% lower all-cause mortality, ~65% fewer ventricular arrhythmias, and ~40% less angina after myocardial infarction.
• Exercise recovery, L-carnitine L-tartrate (2021 RCT, 73 participants, 2 g/day, 5 weeks): improved recovery and soreness and lower creatine kinase vs placebo.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.